BEAM Beam Therapeutics Inc
Company Analysis
Latest News
🟢 Beam Therapeutics is trading 5% up today as markets rebound after Fed decision
Beam Therapeutics is trading 5.06% up at $24.27 as U.S. markets rally following easing policy uncertainty after the Federal Reserve’s September 16 rate...
🔴 Beam Therapeutics falls 4.0% — Biotech Sector Declines on Key Drug Trial Failure and Shifting Investor Sentiment
With Biotech (XBI) down 2.1%, this looks like a sector-led move rather than a company-specific surprise. The biotech sector, as measured by the XBI ETF, fell...
🔴 Beam Therapeutics is trading 4.2% down today after BEAM-302 safety concerns
Beam Therapeutics is trading at $24.13, with a -4.15% move, as investors continue weighing updated BEAM-302 Phase 1/2 safety findings. • Infusion-related...
🔴 Beam Therapeutics is trading 4% down today after BEAM-302 safety concerns
Beam Therapeutics is trading 4% down at $25.75 after investors focused on safety findings in updated BEAM-302 Phase 1/2 data. - Efficacy appeared durable, but...
🔴 Beam Therapeutics is trading 13% down today
Beam Therapeutics is trading 13% down now at $25.80, after falling from the September 4 close of $29.66; the immediate catalyst remains unclear. - On...
🔴 Beam Therapeutics is trading 6.2% down today in pre-market; cause remains unclear
Beam Therapeutics is trading 6.2% down at $27.83 in pre-market, with available company materials not establishing that the positive update caused the...
Beam Therapeutics Surges 9% on Fresh Gene-Editing Data — But Can a One-Time Cure Justify a $3 Billion Bet?
Shares shifted sharply as Beam Therapeutics jumped +9.1% to $32.36 ahead of a morning investor webcast and late-breaking presentation at the European...
🟢 Beam Therapeutics is trading 9.09% up today in pre-market due to positive BEAM-302 data presented at ERS Congress
Beam Therapeutics is trading at $32.36 (+9.09%) as shares rise following the presentation of positive updated BEAM-302 data at the European Respiratory Society...
Farallon Capital Discloses New $241.51M Stake in Beam Therapeutics
In a recent filing, Farallon Capital Management revealed it had established a significant new position in Beam Therapeutics (BEAM), a biotechnology company...
🔴 Beam Therapeutics falls 4.1% — Biotech Sector Declines Amid Fed Rate Hike Fears
With Biotech (XBI) down 2.3%, this looks like a sector-led move rather than a company-specific surprise. The biotech sector, as measured by the XBI ETF, fell...
🟢 Beam Therapeutics is trading 10.1% up today as biotech shares rally
Beam Therapeutics is trading at $31.20 (+10.13%) as biotechnology shares rally, with XBI up 2.06% during the regular session. - No fresh company-specific...
🟢 Beam Therapeutics rises 4.9% — Biotech Sector Gains Amid Broad Market Rally and Positive Sentiment
With Biotech (XBI) up 2.1%, this looks like a sector-led move rather than a company-specific surprise. The biotech sector, represented by the XBI ETF, is...
🔴 Beam Therapeutics is trading 4.5% down today as elevated Treasury yields pressure growth valuations
Beam Therapeutics is trading now at $28.41 (-4.54%) amid broader risk-off pressure on growth stocks. • The Nasdaq Composite is down 0.53%, while elevated...
🟢 Beam Therapeutics is trading 4.56% up today — with no specific catalyst identified
Beam Therapeutics is trading 4.56% up at $29.68, with no specific catalyst identified for the intraday rebound. - No reliable company-specific announcement,...
🔴 Beam Therapeutics falls 5.6% — Biotech Sector Cools Off After Moderna-Sparked Rally
With Biotech (XBI) down 2.5%, this looks like a sector-led move rather than a company-specific surprise. The biotech sector is experiencing a pullback after a...
🟢 Beam Therapeutics is trading 7.3% up today as Moderna’s positive cancer-vaccine results lift biotech
Beam Therapeutics is trading 7.3% up now at $28.51, most likely reflecting biotech-sector momentum after Moderna’s positive personalized cancer-vaccine trial...
🟢 Beam Therapeutics is trading 5% up in pre-market
Beam Therapeutics is trading 5.24% up now at $28.11 versus the August 12 close of $26.71; no fresh company-specific announcement explaining the August 13...
🔴 Beam Therapeutics is trading 4.1% down today after Q2 earnings miss and BofA price target trim
Beam Therapeutics is trading 4.1% down at $27.20 as investors digest a Q2 earnings miss and a price target reduction from Bank of America. • The decline...
🟢 Beam Therapeutics is trading 4.1% up today on extended cash runway and clinical updates
Beam Therapeutics is trading 4.1% up now at $26.98 after the company provided a positive financial outlook and clinical milestones that outweighed...
Beam Therapeutics' second quarter revenue and EPS miss estimates while the company advances its pivotal BEAM-302 trial.
Beam Therapeutics reported a second quarter net loss of $122.7 million, or $1.18 per share, on collaboration revenue of $0.5 million. The company highlighted...